Compare Monster Beverage Corp (MNST) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monster Beverage Corp vs Neurocrine Biosciences Inc — how do they compare? Monster Beverage Corp trades at $43.6 (market cap $84.00B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B). The key difference: Monster Beverage Corp is far larger — about 5.8× Neurocrine Biosciences Inc's market cap, and Monster Beverage Corp is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Monster Beverage Corp for 72 Days and Neurocrine Biosciences Inc for 23 Days on average.
| MNST | NBIX | |
|---|---|---|
Market Cap | $84.00B | $14.60B |
Volume | 8,371,981 | 1,075,694 |
Sector | Consumer Staples | Health |
52-Week High | $49.97 | $185.50 |
52-Week Low | $33.16 | $123.10 |
Typical Hold Time | 72 Days | 23 Days |
Enterprise Value | $82.30B | $14.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monster Beverage (MNST) trades at $43.65, up 0.92% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.30, and maintains robust profitability with a net income margin of 23.08%. Recent news highlights its debt-free balance sheet and international expansion, particularly a 35% surge in overseas sales.
The outlook is mixed: strong fundamentals and analyst consensus support upside to a $98.22 price target, but the stock faces headwinds from rich valuations (P/E 39.7) and technical bearishness. Key risks include inflation pressures and regulatory challenges, such as India's label ban. Institutional sentiment leans bullish, with 52% of analysts rating it Buy.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
